SAN CARLOS, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in November:
Third Quarter 2006 Financial Results and Accomplishments Conference Call & Webcast November 2, 2006 4:30 p.m. ET (1:30 p.m. PT) Dr. Ted W. Love, Chairman and CEO Dr. Michael Levy, SVP, Research and Development Ward Wolff, SVP, Finance and CFO Dial in: 800-561-2718 domestic and 617-614-3525 international with passcode 46778494 Replay: 888-286-8010 domestic and 617-801-6888 international with passcode 87766098, available through Thursday, November 16, 2006. Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site. CIBC World Markets 17th Annual Health Care Conference November 7, 2006 8:00 a.m. ET Dr. Ted W. Love, Chairman and CEO 2006 Credit Suisse Health Care Conference November 16, 2006 4:00 p.m. PT Dr. Ted W. Love, Chairman and CEO Piper Jaffray Health Care Conference November 30, 2006 4:30 p.m. ET Dr. Ted W. Love, Chairman and CEO http://www.piperjaffray.com/hcwebcast
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Foderaro, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nfoderaro@nuvelo.com
Web site: http://www.nuvelo.com/
